Evidence map›Paper›PMID 31311148›Full record

ArticleCancers2019

Sorafenib with Transarterial Chemoembolization Achieves Improved Survival vs. Sorafenib Alone in Advanced Hepatocellular Carcinoma: A Nationwide Population-Based Cohort Study.

Victor C Kok, Yu-Ching Chen, Yang-Yuan Chen, Yu-Chieh Su, Ming-Chang Ku, Jung-Tsung Kuo, Go J Yoshida

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Sorafenib plus transarterial chemoembolizationWorld journal of hepatology · 2024
    Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Victor C KokDivision of Medical Oncology, Department of Internal Medicine, Kuang Tien General Hospital, Taichung 43303, Taiwan. victorkok@asia.edu.tw.ORCID 0000-0003-3440-8154
Yu-Ching ChenDisease Informatics Research Group, Department of Bioinformatics and Medical Engineering, Asia University Taiwan, Taichung 41354, Taiwan.
Yang-Yuan ChenDepartment of Gastroenterology, Changhua Christian Medical Foundation Changhua Christian Hospital, Changhua 50006, Taiwan.
Yu-Chieh SuFaculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan.ORCID 0000-0002-1771-9017
Ming-Chang KuInterventional Radiology Unit, Department of Radiology, Kuang Tien General Hospital, Taichung 43303, Taiwan.
Jung-Tsung KuoArtificial Intelligence Center for Medical Diagnosis, China Medical University Hospital, Taichung 40447, Taiwan.
Go J YoshidaDepartment of Pathology and Oncology, Juntendo University School of Medicine, Tokyo 113-8421, Japan.ORCID 0000-0002-1472-892X

Funding

Ministry of Science and Technology, Taiwan MOST 106-2221-E-468-019Ministry of Science and Technology, Taiwan MOST 106-2632-E-468-002
6 · The paper itself

Abstract

We hypothesized that sorafenib plus transarterial chemoembolization (TACE) would confer survival benefits over sorafenib alone for advanced hepatocellular carcinoma (aHCC). We investigated this while using the population-based All-Cancer Dataset to assemble a cohort (

Indexed as

add-on therapyhepatocellular carcinomapropensity analysissorafenibtransarterial chemoembolization

Identifiers

PMID31311148
PMCPMC6679028

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.